Pathway-Centric Integrative Analysis Identifies RRM2 as a Prognostic Marker in Breast Cancer Associated with Poor Survival and Tamoxifen Resistance
Nagireddy Putluri(Baylor College of Medicine), Arun Sreekumar(University of Michigan–Ann Arbor), Vasanta Putluri(Baylor College of Medicine), Stefan Ambs(University of Maryland, Baltimore), Tapasree Roy Sarkar(The University of Texas MD Anderson Cancer Center), Rachel Schiff(Baylor College of Medicine), Chad J. Creighton(Baylor College of Medicine), Atsushi Terunuma(National Institutes of Health), Tiffany H. Dorsey(Center for Cancer Research), Agostina Nardone(AstraZeneca (Spain)), Bert W. O’Malley(Baylor College of Medicine), John P. Lydon(Baylor University), Xiaoyong Fu(King University), Chad A. Shaw(Baylor College of Medicine), Ramakrishna Kommagani(Washington University in St. Louis), Suman Kumar Maity(Baylor College of Medicine), Gokul M. Das(Roswell Park Comprehensive Cancer Center), Fengju Chen(Baylor College of Medicine), Salil Kumar Bhowmik(Baylor College of Medicine), George Michailidis(University of Michigan)
Cited by 90
Related Papers
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k